CatalystWireBeta

UK small-cap RNS · 19 Aug 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

  1. 17:30
  2. 15:29
  3. 09:50
    Initiation note from QuotedData
    Shaires Holdings Limited - Initiation note from QuotedData
    Dilutive fundraise +0.0% on the day
  4. 07:41
    Q4 Operating Results, Dividend Declaration & CFO Results
    Q4 combined operating profit roughly doubled to £3.2m (vs £1.67m), with South Africa and Ghana both well ahead, in line with the earlier FY2026 upgrades, though a 16% gold price fall squeezed margins.
    Legal & regulatory £0.4m · 1% of mcapoutlook mixedfirst in 6 months +1.4% on the day
    Moved: TSF retreatment and pipeline: Taking control of pipeline application; no feasibility → Pipeline work, water licence, geotechnical studies pending · Brazil new plant build: Licence received, equipment installed and commissioned → Licence received, spirals commissioned · Ghana by-product export decree: Beneficiation rule still affecting all aspects; plant upgrade under way → Permit and licence renewed; upgrade spend done
  5. 07:00
    Completion of RTO & Re-Admission to Trading on AIM
    Completes the Gulf reverse takeover, giving Vast the 49% Aprelevka JV stake and cash-generative production, though sellers receive about 80.23% of the enlarged share capital, so existing holders are heavily diluted.
    Balance-sheet stress / refinancing £7.5m · 12% of mcapoutlook positive5 acquisitions in 3 months – usually about 2 +54.2% on the day
    Moved: Gulf International Minerals reverse takeover: Debt funding signed; General Meeting convened for 18 Aug → Completed; shares re-admitted to AIM on 19 Aug (closed) · Alpha and Mercuria loan default: Binding Glencore loan signed; funds conditional on completion → Funding in place; settlement of loans pending
  6. 07:00
    Transaction Update & Tender Offer Supplement
    This notice only refers back to the 17 August sale of Zhaikmunai and POSITIV to Altaris and says it may be a material change to the tender. The sale is a debt-repayment and wind-down route, so shareholders should expect little.
    Disposal of a part (break-up) −35.0% on the day
    Moved: Delayed SSN and SUN coupon payment: Sale agreed to repay notes; tender offer in dossier unmentioned → Tender offer extended to 2 September · Sale of Kazakhstan operations: SPA signed; conditions precedent pending → SPA signed; conditions precedent pending
  7. 07:00
    ISCIB1+ MHRA CTA Approval for Ph3 trial
    Scancell Receives UK MHRA Clinical Trial Authorization for the Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma
    Project milestones outlook positive +1.1% on the day
    Moved: iSCIB1+ melanoma registration path: Phase 3 funding conditional on US financing → UK MHRA CTA granted; FDA IND cleared
  8. 07:00
    Trading Update Trading update
    iFOREX (LSE:IFRX), a leading fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference ("CFD"), today provides an update on trading and the outlook for the 2026 financial year.
    Upgrade / downgrade cycle below expectationsfirst since Oct 2023 −21.6% on the day
  9. 07:00
    Full Year Trading Update Trading update
    FY26 revenue of £11.3m is in line and underlying EBITDA and cash are slightly ahead. Revenue is mostly licence income, with only £1.5m from the rest, and cash has fallen from £14.4m at January.
    Delisting / take-private £11.3m · 235% of mcapin lineoutlook mixedfirst in 1 year +2.8% on the day
    Moved: Delisting and move to private company: General Meeting adjourned sine die; delisting stalled → Shareholder consultation ongoing after adjourned meeting · Leadership change and cost reset: Further £0.7m saving via delisting proposed → Cost base reduced; further cuts under review · Asian chemical customer SWIR JDA: Milestones met; moving to scale-up → On track for year-one milestones; volumes to double FY27
  10. 07:00
    Pre-Close Trading Update Trading update
    FY26 revenue of £144.9m and adjusted EBITDA of £10.0m match consensus (£144.8m, £9.9m), but FY27 is guided flat, so there is no recovery yet and the guidance is merely confirmed.
    Turnaround plan with targets in lineoutlook mixedfirst since Oct 2023 −3.9% on the day
    Moved: Commercial function overhaul: Refreshed commercial function; Q3 revenue stable → Restructuring costed; H2 revenue flat · CEO succession: Successor named; handover under way → Handover pending; successor starts September
  11. 07:00
    Half-year Results Results
    This is a results report, not a fresh warning. EBITDA fell to $4.4m and the loss after tax was $34.1m on lower prices, and the ilmenite guidance trim to about 800,000 tonnes was already flagged in July.
    Legal & regulatory below expectationsoutlook mixed +7.2% on the day
    Moved: WCP A upgrade and Nataka transition: Built, but nameplate still not consistently reached → Construction complete; nameplate not yet consistent · Value over volume, inventory drawdown: Drawdown continuing; production below plan → Drawdown continuing; H2 recovery expected · Moma Implementation Agreement extension: Talks continuing; no agreement → Talks continuing; significant progress reported

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note